Literature DB >> 20017137

Cooperation of tumor-derived HBx mutants and p53-249(ser) mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line.

Weidong Jiang1, Xin Wei Wang, Tamar Unger, Marshonna Forgues, Jin Woo Kim, S Perwez Hussain, Elise Bowman, Elisa A Spillare, Michael M Lipsky, Jeanne M Meck, Luciane R Cavalli, Bassem R Haddad, Curtis C Harris.   

Abstract

Hepatocellular carcinoma (HCC) is a common cancer, and hepatitis B virus (HBV) is a major etiological agent. Convincing epidemiological and experimental evidence also links HCC to aflatoxin, a naturally occurring mycotoxin that produces a signature p53-249(ser) mutation. Recently, we have reported that tumor-derived HBx variants encoded by HBV exhibited attenuated transactivation and proapoptotic functions but retained their ability to block p53-mediated apoptosis. These results indicate that mutations in HBx may contribute to the development of HCC. In this study, we determined whether tumor-derived HBx mutants along, or in cooperation with p53-249(ser), could alter cell proliferation and chromosome stability of normal human hepatocytes. To test this hypothesis, we established a telomerase immortalized normal human hepatocycte line HHT4 that exhibited a near diploid karyotype and expressed many hepatocyte-specific genes. We found that overexpression one of the tumor-derived HBx mutants, CT, significantly increased colony forming efficiency (CFE) while its corresponding wild-type allele CNT significantly decreased CFE in HHT4 cells. p53-249(ser) rescued CNT-mediated inhibition of colony formation. Although HHT4 cells lacked an anchorage independent growth capability as they did not form any colonies in soft agar, the CT-expressing HHT4 cells could form colonies, which could be significantly enhanced by p53-249(ser). Induction of aneuploidy could be observed in HHT4 cells expressing CT, but additionally recurring chromosome abnormalities could only be detected in cells coexpressing CT and p53-249(ser). Our results are consistent with the hypothesis that certain mutations in HBx and p53 at codon 249 may cooperate in contributing to liver carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20017137      PMCID: PMC2950321          DOI: 10.1002/ijc.25118

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  43 in total

1.  Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis.

Authors:  T I Huo; X W Wang; M Forgues; C G Wu; E A Spillare; C Giannini; C Brechot; C C Harris
Journal:  Oncogene       Date:  2001-06-21       Impact factor: 9.867

2.  Activated ras oncogene collaborates with HBx gene of hepatitis B virus to transform cells by suppressing HBx-mediated apoptosis.

Authors:  Y C Kim; K S Song; G Yoon; M J Nam; W S Ryu
Journal:  Oncogene       Date:  2001-01-04       Impact factor: 9.867

3.  Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication.

Authors:  Wei Wang; Anuradha Budhu; Marshonna Forgues; Xin Wei Wang
Journal:  Nat Cell Biol       Date:  2005-07-24       Impact factor: 28.824

4.  Hepatitis B virus-related insertional mutagenesis in chronic hepatitis B patients as an early drastic genetic change leading to hepatocarcinogenesis.

Authors:  Masahito Minami; Yukiko Daimon; Kojiro Mori; Hidetaka Takashima; Tomoki Nakajima; Yoshito Itoh; Takeshi Okanoue
Journal:  Oncogene       Date:  2005-06-23       Impact factor: 9.867

5.  Hepatitis B 1762T/1764A mutations, hepatitis C infection, and codon 249 p53 mutations in hepatocellular carcinomas from Thailand.

Authors:  Shuang-Yuan Kuang; Suree Lekawanvijit; Niwat Maneekarn; Satawat Thongsawat; Kimberly Brodovicz; Kenrad Nelson; John D Groopman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-02       Impact factor: 4.254

Review 6.  TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.

Authors:  S P Hussain; J Schwank; F Staib; X W Wang; C C Harris
Journal:  Oncogene       Date:  2007-04-02       Impact factor: 9.867

Review 7.  Interactions between hepatitis B virus infection and exposure to aflatoxins in the development of hepatocellular carcinoma: a molecular epidemiological approach.

Authors:  A Sylla; M S Diallo; J Castegnaro; C P Wild
Journal:  Mutat Res       Date:  1999-07-16       Impact factor: 2.433

Review 8.  Senescence and immortalization: role of telomeres and telomerase.

Authors:  Jerry W Shay; Woodring E Wright
Journal:  Carcinogenesis       Date:  2004-10-07       Impact factor: 4.944

9.  Interaction of hepatitis B viral oncoprotein with cellular target HBXIP dysregulates centrosome dynamics and mitotic spindle formation.

Authors:  Yunfei Wen; Vladislav S Golubkov; Alex Y Strongin; Wei Jiang; John C Reed
Journal:  J Biol Chem       Date:  2007-11-21       Impact factor: 5.157

10.  HBV X protein targets hBubR1, which induces dysregulation of the mitotic checkpoint.

Authors:  S Kim; S-Y Park; H Yong; J K Famulski; S Chae; J-H Lee; C-M Kang; H Saya; G K Chan; H Cho
Journal:  Oncogene       Date:  2008-01-14       Impact factor: 9.867

View more
  21 in total

Review 1.  Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis.

Authors:  Yan Liu; Chung-Chou H Chang; Gary M Marsh; Felicia Wu
Journal:  Eur J Cancer       Date:  2012-03-08       Impact factor: 9.162

2.  Association of Aflatoxin and Gallbladder Cancer.

Authors:  Jill Koshiol; Yu-Tang Gao; Michael Dean; Patricia Egner; Chirag Nepal; Kristine Jones; Bingsheng Wang; Asif Rashid; Wen Luo; Alison L Van Dyke; Catterina Ferreccio; Michael Malasky; Ming-Chang Shen; Bin Zhu; Jesper B Andersen; Allan Hildesheim; Ann W Hsing; John Groopman
Journal:  Gastroenterology       Date:  2017-04-17       Impact factor: 22.682

Review 3.  Molecular mechanism of hepatitis B virus X protein function in hepatocarcinogenesis.

Authors:  Ming Geng; Xuan Xin; Li-Quan Bi; Lu-Ting Zhou; Xiao-Hong Liu
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

4.  Oncogenic Activation of the RNA Binding Protein NELFE and MYC Signaling in Hepatocellular Carcinoma.

Authors:  Hien Dang; Atsushi Takai; Marshonna Forgues; Yotsowat Pomyen; Haiwei Mou; Wen Xue; Debashish Ray; Kevin C H Ha; Quaid D Morris; Timothy R Hughes; Xin Wei Wang
Journal:  Cancer Cell       Date:  2017-07-10       Impact factor: 31.743

Review 5.  Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma.

Authors:  Ashraf Ali; Hany Abdel-Hafiz; Mohd Suhail; Amany Al-Mars; Mohammad Khalid Zakaria; Kaneez Fatima; Sultan Ahmad; Esam Azhar; Adeel Chaudhary; Ishtiaq Qadri
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

6.  Interaction of mutant hepatitis B X protein with p53 tumor suppressor protein affects both transcription and cell survival.

Authors:  Shoba Iyer; John D Groopman
Journal:  Mol Carcinog       Date:  2011-03-22       Impact factor: 4.784

Review 7.  Transposon mouse models to elucidate the genetic mechanisms of hepatitis B viral induced hepatocellular carcinoma.

Authors:  Amy P Chiu; Barbara R Tschida; Lilian H Lo; Branden S Moriarity; Dewi K Rowlands; David A Largaespada; Vincent W Keng
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

8.  Global geographical overlap of aflatoxin and hepatitis C: controlling risk factors for liver cancer worldwide.

Authors:  D L Palliyaguru; F Wu
Journal:  Food Addit Contam Part A Chem Anal Control Expo Risk Assess       Date:  2013-01-02

Review 9.  Somatic TP53 Mutations in the Era of Genome Sequencing.

Authors:  Pierre Hainaut; Gerd P Pfeifer
Journal:  Cold Spring Harb Perspect Med       Date:  2016-11-01       Impact factor: 6.915

10.  AGO2 Mediates MYC mRNA Stability in Hepatocellular Carcinoma.

Authors:  Kai Zhang; Yotsawat Pomyen; Anna E Barry; Sean P Martin; Subreen Khatib; Lucy Knight; Marshonna Forgues; Dana A Dominguez; Ravinder Parhar; Ashesh P Shah; Adam S Bodzin; Xin Wei Wang; Hien Dang
Journal:  Mol Cancer Res       Date:  2020-01-15       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.